Novo Nordisk is a global healthcare company headquartered in Bagsværd, Denmark. Founded in 1923, it researches, develops, manufactures, and markets medicines for serious chronic diseases. The company is listed on Nasdaq Copenhagen, with American Depositary Receipts traded in the U.S.
Core areas include diabetes and obesity, as well as rare endocrine and blood disorders. Its portfolio spans human and analogue insulins, GLP-1–based therapies, and other peptide and protein biologics. Novo Nordisk operates extensive bioprocessing, active pharmaceutical ingredient production, formulation, and fill–finish facilities worldwide, and collaborates with academic and industry partners on emerging modalities such as cell therapy.
Also known as Novo and NVO.
chemXplore tracks 5 projects involving Novo Nordisk, of which 3 are active.
Novo Nordisk's role on them: Owner.
3 expansion.
Targeting: Glucagon-like peptide-1 (1)
CagriSema 1.0/1.0 delivered greater weight loss than tirzepatide 5 mg and 21% vs 2% vs placebo in obesity trial; HbA1c reduction was non‑inferior. FDA decision expected Q4 2026.
Once-weekly somapacitan (Sogroya) receives CHMP positive opinion for children with idiopathic short stature; European Commission decision expected later this year.
First FVIIIa mimetic offering monthly, two‑week and weekly subcutaneous prophylaxis in a single‑use pre-filled pen; CHMP has issued a positive opinion for EU approval.
Phase 3b switch study shows denecimig well tolerated after direct switch from emicizumab; pen injector preferred and thrombin generation rose to normal without excess clotting.
First once-weekly basal insulin for adults with type 2 diabetes; one weekly injection replaces seven daily doses, available at 70,000+ pharmacies with affordability options from $35/month.
Strategic cloud and AI tie‑up to speed drug discovery, deploy agentic AI, and compress time from target to first human dose via a London co‑innovation hub.
Ziltivekimab lowered free IL‑6 and hsCRP but did not reduce cardiovascular events; safety similar to placebo except for more serious infections; related trials continue with H1 2027 readouts.
OASIS data showed ~17% mean weight loss and ~1 in 3 reached ≥20%; safety comparable to injectable semaglutide; wider roll‑out planned in H2 2026.
